JP2005247873A5 - - Google Patents

Download PDF

Info

Publication number
JP2005247873A5
JP2005247873A5 JP2005159852A JP2005159852A JP2005247873A5 JP 2005247873 A5 JP2005247873 A5 JP 2005247873A5 JP 2005159852 A JP2005159852 A JP 2005159852A JP 2005159852 A JP2005159852 A JP 2005159852A JP 2005247873 A5 JP2005247873 A5 JP 2005247873A5
Authority
JP
Japan
Prior art keywords
acid
hydroxy
diphosphonic acid
bisphosphonate
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2005159852A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005247873A (ja
JP5005188B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2005247873A publication Critical patent/JP2005247873A/ja
Publication of JP2005247873A5 publication Critical patent/JP2005247873A5/ja
Application granted granted Critical
Publication of JP5005188B2 publication Critical patent/JP5005188B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2005159852A 2000-06-20 2005-05-31 ビホスホネートの投与法 Expired - Lifetime JP5005188B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US59713500A 2000-06-20 2000-06-20
US09/597,135 2000-06-20
US26768901P 2001-02-09 2001-02-09
US60/267,689 2001-02-09

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2002503265A Division JP4722375B2 (ja) 2000-06-20 2001-06-18 ビホスホネートの投与法

Publications (3)

Publication Number Publication Date
JP2005247873A JP2005247873A (ja) 2005-09-15
JP2005247873A5 true JP2005247873A5 (https=) 2008-07-17
JP5005188B2 JP5005188B2 (ja) 2012-08-22

Family

ID=26952565

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002503265A Expired - Lifetime JP4722375B2 (ja) 2000-06-20 2001-06-18 ビホスホネートの投与法
JP2005159852A Expired - Lifetime JP5005188B2 (ja) 2000-06-20 2005-05-31 ビホスホネートの投与法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2002503265A Expired - Lifetime JP4722375B2 (ja) 2000-06-20 2001-06-18 ビホスホネートの投与法

Country Status (24)

Country Link
US (1) US8052987B2 (https=)
EP (1) EP1296689B3 (https=)
JP (2) JP4722375B2 (https=)
KR (1) KR100864743B1 (https=)
CN (1) CN1272013C (https=)
AT (1) ATE304856T1 (https=)
AU (2) AU7410901A (https=)
BR (1) BR0111806A (https=)
CA (1) CA2410201C (https=)
CY (2) CY1113740T1 (https=)
CZ (1) CZ301972B6 (https=)
DE (1) DE60113537T3 (https=)
DK (1) DK1296689T3 (https=)
ES (2) ES2394211T3 (https=)
HU (1) HU228400B1 (https=)
IL (2) IL153229A0 (https=)
MX (1) MXPA02012682A (https=)
NO (1) NO330459B1 (https=)
NZ (1) NZ523086A (https=)
PL (1) PL203087B1 (https=)
PT (1) PT1591122E (https=)
SK (1) SK287278B6 (https=)
TW (1) TWI289451B (https=)
WO (1) WO2001097788A2 (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US7658938B2 (en) * 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
ES2394211T3 (es) 2000-06-20 2013-01-23 Novartis Ag Procedimiento de administración de bifosfonatos
EP1192945A3 (en) * 2000-09-21 2004-03-03 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating osteoarthritis
EP1383509A4 (en) * 2001-04-03 2005-10-26 Royal Alexandra Hosp Children MEDICAMENT FOR USE IN BONE TRAINING
US20050070504A1 (en) * 2001-12-21 2005-03-31 The Procter & Gamble Co. Risedronate compositions and their methods of use
GB0204756D0 (en) * 2002-02-28 2002-04-17 Novartis Ag Organic compounds
KR20060058151A (ko) * 2002-05-10 2006-05-29 에프. 호프만-라 로슈 아게 골다공증 치료 및 예방용 비스포스폰산
AU2003270196A1 (en) * 2002-09-16 2004-04-30 Kenneth W. Lyles Method for preventing or reducing secondary fractures after hip fracture
CN1705485A (zh) * 2002-10-15 2005-12-07 诺瓦提斯公司 施用双膦酸类化合物的方法
ES2291749T5 (es) 2002-12-20 2011-07-21 F. Hoffmann-La Roche Ag Formulación de altas dosis de ibandronato.
JPWO2005072746A1 (ja) * 2004-01-30 2007-10-11 アステラス製薬株式会社 Ｐ２ｘ受容体阻害剤
EP1713489B1 (en) * 2004-08-23 2011-01-19 Teva Pharmaceutical Industries Ltd Crystalline form of ibandronate sodium and processes for preparation thereof
US7709508B2 (en) 2004-12-09 2010-05-04 Merck Sharp & Dohme Estrogen receptor modulators
NZ555316A (en) * 2004-12-09 2009-08-28 Merck & Co Inc Estrogen receptor modulators
US8071574B2 (en) * 2005-02-22 2011-12-06 John Dennis Bobyn Implant improving local bone formation
US7473684B2 (en) * 2005-09-16 2009-01-06 Selamine Limited Bisphosphonate formulation
KR101191322B1 (ko) * 2006-04-07 2012-10-16 메리온 리서치 Ⅲ 리미티드 증진제를 함유하는 고형 경구용 투여 제형
US20090075941A1 (en) * 2006-04-21 2009-03-19 The Uab Research Foundation Treating neoplasms
US20080139514A1 (en) * 2006-11-29 2008-06-12 Subhash Pandurang Gore Diphosphonic acid pharmaceutical compositions
US20100068211A1 (en) * 2008-02-08 2010-03-18 Bateman Ted A Use of antiresorptive compounds to prevent ionizing radiation-induced activation of osteoclasts and resulting bone loss
CN107096012A (zh) * 2008-05-07 2017-08-29 诺和诺德股份有限公司 肽的组合物及其制备方法
US20100215743A1 (en) * 2009-02-25 2010-08-26 Leonard Thomas W Composition and drug delivery of bisphosphonates
DK2459176T3 (en) 2009-07-31 2017-12-04 Gruenenthal Gmbh Crystallization process and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
CN105920023A (zh) 2009-09-01 2016-09-07 杜克大学 双膦酸类组合物及其治疗心力衰竭的方法
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
WO2011120033A1 (en) * 2010-03-26 2011-09-29 Merrion Research Iii Limited Pharmaceutical compositions of selective factor xa inhibitors for oral administration
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
EP2661273A4 (en) 2011-01-07 2014-06-04 Merrion Res Iii Ltd IRON PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION
CN104010647A (zh) 2011-11-16 2014-08-27 杜克大学 用于治疗和/或减轻心功能障碍的双膦酸盐组合物及方法
CN103623465B (zh) * 2013-11-21 2015-12-30 彭江 一种可局部调节成破骨活性的组织工程骨支架及制备方法
US10265384B2 (en) 2015-01-29 2019-04-23 Novo Nordisk A/S Tablets comprising GLP-1 agonist and enteric coating
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability
KR20180115979A (ko) * 2017-04-14 2018-10-24 연세대학교 산학협력단 비스포스포네이트를 포함하는 만성 이식신 기능부전 예방 또는 치료용 조성물
GB201716716D0 (en) 2017-10-12 2017-11-29 Univ Of Hertfordshire Higher Education Corporation Method for coating particles
JP2022536222A (ja) * 2018-11-02 2022-08-15 アンパサンド バイオファーマシューティカルズ インコーポレイテッド 局所的に施用される緩衝液によるカチオン過負荷および電解質平衡異常のリスクの管理
KR102049233B1 (ko) * 2019-01-14 2019-11-28 연세대학교 산학협력단 비스포스포네이트를 포함하는 만성 이식신 기능부전 예방 또는 치료용 조성물

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US594329A (en) * 1897-11-23 Socket or collet
DE3232959A1 (de) 1982-09-04 1984-03-08 Hoechst Ag, 6230 Frankfurt Substituierte benzolsulfonsaeureester, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE3583887D1 (de) 1984-04-30 1991-10-02 Procter & Gamble Ausruestung fuer die behandlung der osteoporose.
US4822609A (en) 1984-12-21 1989-04-18 The Procter & Gamble Company Treatment of osteoporosis
US4812304A (en) 1984-12-21 1989-03-14 The Procter & Gamble Company Treatment of osteoporosis
US4812311A (en) 1984-12-21 1989-03-14 The Procter & Gamble Company Kit for use in the treatment of osteoporosis
US4761406A (en) 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
ES2038692T4 (es) 1986-11-21 2012-02-10 Novartis Ag Procedimiento para la obtencion de acidos alcanodifosfonicos substituidos.
JPH07502507A (ja) 1991-12-17 1995-03-16 プロクター、エンド、ギャンブル、ファーマスーティカルズ、インコーポレーテッド ビスホスホネート類及び副甲状腺ホルモンを用いた骨粗鬆症の治療方法
DK0648120T3 (da) 1992-06-30 1998-01-19 Procter & Gamble Pharma Anvendelse af phosphonater til behandling af osteoporose
AU670337B2 (en) 1992-11-30 1996-07-11 Novartis Ag Use of certain methanebisphosphonic acid derivatives in fracture healing
EP0600834A1 (en) 1992-11-30 1994-06-08 Ciba-Geigy Ag Use of methanebisphosphonic acid derivatives for the manufacture of a medicament for fracture healing
US5366965A (en) 1993-01-29 1994-11-22 Boehringer Mannheim Gmbh Regimen for treatment or prophylaxis of osteoporosis
GB9408775D0 (en) 1994-05-04 1994-06-22 Ciba Geigy Ag Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration
KR970705399A (ko) 1994-09-09 1997-10-09 레이셔 야코버스 코넬리스 골다공증용 포스포네이트 및 부갑상성 호르몬(phosphonates and parathyroid hormone for osteoporosis)
WO1996007417A1 (en) 1994-09-09 1996-03-14 The Procter & Gamble Company Methods for the treatment of osteoporosis using bone active phosphonates and parathyroid hormone
ATE290871T1 (de) 1995-09-29 2005-04-15 Novartis Pharma Gmbh Verfahren zur behandlung navikularer krankheiten bei pferden
US5735810A (en) 1996-06-14 1998-04-07 Becton Dickinson And Company Device for the iontophoretic administration of bisphosphonates
US5730715A (en) 1996-06-14 1998-03-24 Becton Dickinson And Company Method for the iontophoretic administration of bisphosphonates
SE9702401D0 (sv) 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
US6432932B1 (en) 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
US6015801A (en) * 1997-07-22 2000-01-18 Merck & Co., Inc. Method for inhibiting bone resorption
US5994329A (en) 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
PT1175904E (pt) 1997-07-22 2007-04-30 Merck & Co Inc Alendronato para utilização no tratamento da osteoporose
FI109088B (fi) 1997-09-19 2002-05-31 Leiras Oy Tabletti ja menetelmä sen valmistamiseksi
SE9703691D0 (sv) * 1997-10-10 1997-10-10 Astra Ab Pharmaceutical compositions
IT1296495B1 (it) 1997-11-21 1999-06-25 Prodotti Antibiotici Spa Impiego di bisfosfonati nella preparazione di forme farmaceutiche per somministrazione intramuscolare
GB2336311A (en) 1998-04-15 1999-10-20 Merck & Co Inc Bisphosphonate Dosing Regimen
CA2308532C (en) 1999-05-12 2005-11-29 Gador S.A. Use of bisphosphonates for the treatment of osteogenesis imperfecta
PL351674A1 (en) * 1999-05-21 2003-05-19 Novartis Ag Use of bisphosphonic acids for treating angiogenesis
AU2270101A (en) 1999-12-20 2001-07-03 Merck & Co., Inc. Pharmaceutical kit
GB0012209D0 (en) 2000-05-19 2000-07-12 Novartis Ag Organic compounds
ES2394211T3 (es) 2000-06-20 2013-01-23 Novartis Ag Procedimiento de administración de bifosfonatos

Similar Documents

Publication Publication Date Title
JP2005247873A5 (https=)
CA2410201A1 (en) Zoledronic acid or salts thereof for use in the treatment of conditions of abnormally increased bone turnover
JP2006506365A5 (https=)
RU2003133773A (ru) Фармацевтическое применение бисфосфонатов
JP2004528340A5 (https=)
RU2003117702A (ru) Применение бисфосфонатов для лечения боли
US20070161603A1 (en) Method of administering bisphosphonates
JP2002529490A5 (https=)
AU2002217061A1 (en) Use of bisphosphonates for pain treatment
JP2003500352A5 (https=)
JP4802096B2 (ja) ビスホスホネートを含む医薬製品
AU775079B2 (en) Pharmaceutical compositions and uses
RU2002121643A (ru) Фармацевтическая парентеральная композиция, содержащая бифосфонат
JP2006500401A5 (https=)
JP2009522369A5 (https=)
RU2003100503A (ru) Способ введения бисфосфонатов
RU2001133352A (ru) Применение бисфосфоновых кислот для лечения ангиогенеза
EP1591122A1 (en) Method of administering bisphosphonates
HK1068550A (en) Use of bisphosphonates for pain treatment